Market capitalization | $2.83b |
Enterprise Value | $2.81b |
P/E (TTM) P/E ratio | 917.28 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 12.38 |
P/S ratio (TTM) P/S ratio | 12.47 |
P/B ratio (TTM) P/B ratio | 10.97 |
Revenue growth (TTM) Revenue growth | 22.48% |
Revenue (TTM) Revenue | $226.84m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
8 Analysts have issued a Vericel Corporation forecast:
8 Analysts have issued a Vericel Corporation forecast:
Sep '24 |
+/-
%
|
||
Revenue | 227 227 |
22%
22%
|
|
Gross Profit | 162 162 |
29%
29%
|
|
EBITDA | 3.95 3.95 |
179%
179%
|
EBIT (Operating Income) EBIT | -1.23 -1.23 |
91%
91%
|
Net Profit | 3.55 3.55 |
135%
135%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Dominick Colangelo |
Employees | 314 |
Founded | 1989 |
Website | www.vcel.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.